Clinical Application of CNS-Acting Agents in FSD
Version of Record online: 22 OCT 2007
The Journal of Sexual Medicine
Special Issue: FEMALE SEXUAL DYSFUNCTION AND THE CNS
Volume 4, Issue Supplement s4, pages 280–290, November 2007
How to Cite
Perelman, M. A. (2007), Clinical Application of CNS-Acting Agents in FSD. Journal of Sexual Medicine, 4: 280–290. doi: 10.1111/j.1743-6109.2007.00611.x
- Issue online: 22 OCT 2007
- Version of Record online: 22 OCT 2007
- Female Sexual Dysfunction;
- Combination Therapy;
- Multidisciplinary Approach;
- Sexual Tipping Point
Introduction. Human sexual response involves a complex sequencing of interrelated mind/body processes. Few treatment options exist that address the complex multilayered etiological determinants of female sexual dysfunction (FSD).
Aim. Review and evaluate the clinical application of centrally acting agents for the treatment of FSD, with particular emphasis on recently released data on bremelanotide.
Methods. Review of literature on the treatment of FSD.
Results. Approaches to FSD treatment have ranged from psychological counseling through a variety of medical interventions along the physiological pathways of sexual function and dysfunction. Despite a great deal of research, especially into hormonal and vasoactive substances, few therapeutics have broad consistent applicability and have withstood scientific scrutiny. Recent clinical trials have investigated the potential role of agents which act on the central nervous system for the treatment of FSD.
Conclusions. While the recent data supporting the therapeutic use of centrally acting agents as a monotherapy for FSD are cautiously encouraging, there would seem to be tremendous promise for these centrally acting compounds to be integrated with treatment approaches that utilize other pathways in a multilayered, individualized approach to care. Perelman MA. Clinical application of CNS-acting agents in FSD. J Sex Med 2007;4(suppl 4):280–290.